Dr. Franzmann is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Office
1666 NW 10 Ave
Miami, FL 33136Phone+1 305-545-5224Fax+1 305-243-1283
Summary
- Dr. Elizabeth Franzmann is an otolaryngologist in Miami, FL and is affiliated with multiple hospitals in the area, including Miami Veterans Affairs Healthcare System, University of Miami Hospital, and University of Miami Hospital and Clinics. She received her medical degree from David Geffen School of Medicine at UCLA and has been in practice 22 years. She specializes in head & neck oncologic surgery and is experienced in head and neck oncology, head and neck oncology, head and neck neoplasms. Her research interests are in early detection of oral and oropharyngeal cancer.
Education & Training
- University of Miami/Jackson Health SystemResidency, Otolaryngology - Head and Neck Surgery, 2000 - 2002
- University of Miami/Jackson Health SystemInternship, Transitional Year, 1995 - 1996
- David Geffen School of Medicine at UCLAClass of 1995
Certifications & Licensure
- FL State Medical License 1997 - 2025
- American Board of Otolaryngology - Head and Neck Surgery Otolaryngology
Awards, Honors, & Recognition
- Fellow (FACS) American College of Surgeons
- Fellow (FAAO-HNS) American Academy of Otolaryngology - Head and Neck Surgery
Clinical Trials
- Cetuximab + Taxotere With Low Dose Fractionated Radiation for Head and Neck Carcinoma Start of enrollment: 2013 Jun 03
- A Proof of Concept Trial Investigating Safety and Efficacy of APG-157 in Oral Dysplasia Start of enrollment: 2023 May 24
Roles: Contact, Sponsor-Investigator, Principal Investigator
- Safety and Efficacy of APG-157 in Head and Neck Cancer Start of enrollment: 2022 Apr 22
Publications & Presentations
PubMed
- 63 citationsCD44 interacts with EGFR and promotes head and neck squamous cell carcinoma initiation and progressionAymee Perez, David M. Neskey, Judy Wen, Lutecia Pereira, Erika P. Reategui
Oral Oncology. 2013-04-01 - 34 citationsSalivary protein and solCD44 levels as a potential screening tool for early detection of head and neck squamous cell carcinoma.Elizabeth J. Franzmann, Erika P. Reategui, Lutecia Pereira, Felipe Pedroso, Debbie Elizabeth Joseph
Head & Neck. 2012-05-01 - 23 citationsRisk Stratification System for Oral Cancer ScreeningLutécia H. Mateus Pereira, Isildinha M. Reis, Erika P. Reategui, Claudia Gordon, Sandra Saint-Victor
Cancer Prevention Research. 2016-06-01
Press Mentions
- Sylvester Cancer Tip Sheet for August 2024August 22nd, 2024
- Mouthwash-Based Test Could Predict Head and Neck Cancer RecurrenceAugust 20th, 2024
- Mouthwash: New Life-Saving Cancer Detection ToolAugust 19th, 2024
- Join now to see all
Grant Support
- Salivary Soluble Markers In Head And Neck CancerNational Cancer Institute2007–2010
- Salivary Soluble CD44: A Molecular Marker For Head And *National Cancer Institute2005
- Salivary Soluble CD44: A Molecular Marker For HnsccNational Cancer Institute2004
Professional Memberships
- Fellow
- Member
Industry Relationships
- Scientific Founder, Vigilant Biosciences
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: